Cytoreductive Nephrectomy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2015

AUTHORS

Scott E. Delacroix , Brian F. Chapin , Jose Karam , Christopher G. Wood

ABSTRACT

Cytoreductive nephrectomy (CN) remains an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitinib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, highlight the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC. More... »

PAGES

157-171

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_10

DOI

http://dx.doi.org/10.1007/978-3-319-17903-2_10

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009111826


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA", 
          "id": "http://www.grid.ac/institutes/grid.279863.1", 
          "name": [
            "Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delacroix", 
        "givenName": "Scott E.", 
        "id": "sg:person.01274241527.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274241527.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA", 
            "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chapin", 
        "givenName": "Brian F.", 
        "id": "sg:person.01202352702.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202352702.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA", 
            "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karam", 
        "givenName": "Jose", 
        "id": "sg:person.01246663563.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246663563.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA", 
            "Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015", 
    "datePublishedReg": "2015-01-01", 
    "description": "Cytoreductive nephrectomy (CN) remains an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitinib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, highlight the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.", 
    "editor": [
      {
        "familyName": "Lara", 
        "givenName": "Primo N.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-17903-2_10", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-17902-5", 
        "978-3-319-17903-2"
      ], 
      "name": "Kidney Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "cytoreductive nephrectomy", 
      "optimal patient selection", 
      "overall survival", 
      "metastatic RCC", 
      "patient selection", 
      "timing of CN", 
      "multidisciplinary treatment paradigm", 
      "large phase III", 
      "treatment of patients", 
      "renal cell carcinoma", 
      "tyrosine kinase inhibitors", 
      "cytokine therapy", 
      "cell carcinoma", 
      "primary tumor", 
      "treatment paradigm", 
      "sunitinib malate", 
      "FDA approval", 
      "patients", 
      "surgery", 
      "kinase inhibitors", 
      "phase III", 
      "therapy paradigm", 
      "nephrectomy", 
      "therapy", 
      "trials", 
      "RCC", 
      "treatment", 
      "risk", 
      "carcinoma", 
      "tumors", 
      "cancer", 
      "physicians", 
      "survival", 
      "inhibitors", 
      "approval", 
      "future methods", 
      "controversy", 
      "integral part", 
      "role", 
      "timing", 
      "data", 
      "optimal integration", 
      "removal", 
      "paradigm", 
      "selection", 
      "malate", 
      "results", 
      "part", 
      "method", 
      "chapter", 
      "integration", 
      "historical evolution", 
      "evolution"
    ], 
    "name": "Cytoreductive Nephrectomy", 
    "pagination": "157-171", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009111826"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-17903-2_10"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-17903-2_10", 
      "https://app.dimensions.ai/details/publication/pub.1009111826"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_308.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-17903-2_10"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_10'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_10'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_10'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_10'


 

This table displays all metadata directly associated to this object as RDF triples.

143 TRIPLES      22 PREDICATES      78 URIs      71 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-17903-2_10 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N7c7ae29940ff433babf9c630756cc817
4 schema:datePublished 2015
5 schema:datePublishedReg 2015-01-01
6 schema:description Cytoreductive nephrectomy (CN) remains an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitinib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, highlight the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.
7 schema:editor N315cb84531724d8fba57414688722c89
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nc08f4355117347d586fb6fc69289ef26
11 schema:keywords FDA approval
12 RCC
13 approval
14 cancer
15 carcinoma
16 cell carcinoma
17 chapter
18 controversy
19 cytokine therapy
20 cytoreductive nephrectomy
21 data
22 evolution
23 future methods
24 historical evolution
25 inhibitors
26 integral part
27 integration
28 kinase inhibitors
29 large phase III
30 malate
31 metastatic RCC
32 metastatic renal cell carcinoma
33 method
34 multidisciplinary treatment paradigm
35 nephrectomy
36 optimal integration
37 optimal patient selection
38 overall survival
39 paradigm
40 part
41 patient selection
42 patients
43 phase III
44 physicians
45 primary tumor
46 removal
47 renal cell carcinoma
48 results
49 risk
50 role
51 selection
52 sunitinib malate
53 surgery
54 survival
55 therapy
56 therapy paradigm
57 timing
58 timing of CN
59 treatment
60 treatment of patients
61 treatment paradigm
62 trials
63 tumors
64 tyrosine kinase inhibitors
65 schema:name Cytoreductive Nephrectomy
66 schema:pagination 157-171
67 schema:productId N7452a3dcb97741aba902663a151c3fdf
68 Na34f4ad7df4048e4b149ee1cbc6a19c8
69 schema:publisher N54f7dba37a5e44b8b8d63e065128952a
70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009111826
71 https://doi.org/10.1007/978-3-319-17903-2_10
72 schema:sdDatePublished 2022-09-02T16:13
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher N2ed5ad7ca87343889598aee9837e42a5
75 schema:url https://doi.org/10.1007/978-3-319-17903-2_10
76 sgo:license sg:explorer/license/
77 sgo:sdDataset chapters
78 rdf:type schema:Chapter
79 N28beb63cf6f24de6a771f49590069de1 schema:familyName Lara
80 schema:givenName Primo N.
81 rdf:type schema:Person
82 N2ed5ad7ca87343889598aee9837e42a5 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 N315cb84531724d8fba57414688722c89 rdf:first N28beb63cf6f24de6a771f49590069de1
85 rdf:rest N3490a9153ea2411fb1c7623c38dc6126
86 N3490a9153ea2411fb1c7623c38dc6126 rdf:first Ncdd26433f34d44578122b3e0a1a63747
87 rdf:rest rdf:nil
88 N54f7dba37a5e44b8b8d63e065128952a schema:name Springer Nature
89 rdf:type schema:Organisation
90 N569c85b2cb804be99dc1c3ef553d43dd rdf:first sg:person.01040121722.56
91 rdf:rest rdf:nil
92 N7452a3dcb97741aba902663a151c3fdf schema:name doi
93 schema:value 10.1007/978-3-319-17903-2_10
94 rdf:type schema:PropertyValue
95 N7c7ae29940ff433babf9c630756cc817 rdf:first sg:person.01274241527.45
96 rdf:rest Nc5dc512b549044b08459806ed2b56f51
97 Na34f4ad7df4048e4b149ee1cbc6a19c8 schema:name dimensions_id
98 schema:value pub.1009111826
99 rdf:type schema:PropertyValue
100 Nc08f4355117347d586fb6fc69289ef26 schema:isbn 978-3-319-17902-5
101 978-3-319-17903-2
102 schema:name Kidney Cancer
103 rdf:type schema:Book
104 Nc5dc512b549044b08459806ed2b56f51 rdf:first sg:person.01202352702.54
105 rdf:rest Neeb1d357b4094cf9bb0c74f8b2b60912
106 Ncdd26433f34d44578122b3e0a1a63747 schema:familyName Jonasch
107 schema:givenName Eric
108 rdf:type schema:Person
109 Neeb1d357b4094cf9bb0c74f8b2b60912 rdf:first sg:person.01246663563.08
110 rdf:rest N569c85b2cb804be99dc1c3ef553d43dd
111 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
112 schema:name Medical and Health Sciences
113 rdf:type schema:DefinedTerm
114 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
115 schema:name Oncology and Carcinogenesis
116 rdf:type schema:DefinedTerm
117 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
118 schema:familyName Wood
119 schema:givenName Christopher G.
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
121 rdf:type schema:Person
122 sg:person.01202352702.54 schema:affiliation grid-institutes:grid.240145.6
123 schema:familyName Chapin
124 schema:givenName Brian F.
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202352702.54
126 rdf:type schema:Person
127 sg:person.01246663563.08 schema:affiliation grid-institutes:grid.240145.6
128 schema:familyName Karam
129 schema:givenName Jose
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246663563.08
131 rdf:type schema:Person
132 sg:person.01274241527.45 schema:affiliation grid-institutes:grid.279863.1
133 schema:familyName Delacroix
134 schema:givenName Scott E.
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274241527.45
136 rdf:type schema:Person
137 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA
138 schema:name Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA
139 Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, 77030, Houston, TX, USA
140 rdf:type schema:Organization
141 grid-institutes:grid.279863.1 schema:alternateName Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA
142 schema:name Department of Urology, Louisiana State University School of Medicine, 1542 Tulane Avenue, Suite 547, 70112, New Orleans, LA, USA
143 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...